ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
2.850
+0.170 (6.34%)
At close: Jun 24, 2025, 4:00 PM
2.860
+0.010 (0.35%)
After-hours: Jun 24, 2025, 7:14 PM EDT
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover ADC Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.8, which forecasts a 173.68% increase in the stock price over the next year. The lowest target is $5 and the highest is $10.
Price Target: $7.8 (+173.68%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADC Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +75.44% | Jun 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +250.88% | Jun 13, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +180.70% | May 15, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +145.61% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +180.70% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
78.38M
from 70.84M
Increased by 10.65%
Revenue Next Year
90.18M
from 78.38M
Increased by 15.05%
EPS This Year
-1.36
from -1.62
EPS Next Year
-1.33
from -1.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 83.8M | 122.4M | 187.6M | ||
| Avg | 78.4M | 90.2M | 153.6M | ||
| Low | 72.2M | 71.1M | 127.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.3% | 56.2% | 108.0% | ||
| Avg | 10.7% | 15.1% | 70.4% | ||
| Low | 1.9% | -9.2% | 41.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.38 | -0.96 | -0.66 |
| Avg | -1.36 | -1.33 | -0.95 |
| Low | -1.95 | -2.06 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.